MEN2

MEN2 stands for multiple endocrine neoplasia type 2, an autosomal dominant hereditary cancer syndrome caused by germline activating mutations in the RET proto-oncogene on chromosome 10q11.2. The syndrome is characterized by a strong predisposition to medullary thyroid carcinoma (MTC) arising from thyroid C cells, often together with pheochromocytoma (a tumor of the adrenal medulla) and, depending on the specific genotype, primary hyperparathyroidism or characteristic developmental features. Clinically, MEN2 is usually partitioned into MEN2A (the most common subtype, with MTC, pheochromocytoma, and variable hyperparathyroidism), MEN2B (MTC, pheochromocytoma, and additional features such as mucosal neuromas), and familial MTC. A modern consensus overview is Wells et al., Thyroid 2015 (NLM 25810047).

The RET mutation spectrum

RET encodes a receptor tyrosine kinase expressed in neural-crest-derived tissues. In MEN2A, the activating mutations most commonly affect cysteine residues in the extracellular domain (codons 609, 611, 618, 620, and 634), which promote ligand-independent receptor dimerization. In MEN2B, the characteristic mutation is in the intracellular kinase domain (codon 918, M918T), which changes substrate specificity and produces a more aggressive phenotype with earlier MTC onset. The genotype-phenotype correlation is strong enough that the mutation identified in an affected family is used to stratify risk and timing of monitoring according to published American Thyroid Association guidelines (Wells et al., Thyroid 2015 (NLM 25810047)). The underlying molecular biology is reviewed in Mulligan, Nat. Rev. Cancer 2014 (NLM 24561444).

Why MEN2 appears in peptide-research contexts

MEN2 is directly relevant to the published research on GLP-1 and GIP receptor agonists because GLP-1R agonism in preclinical rodent models (rats and mice) has been associated with C-cell hyperplasia and, at high exposures over prolonged periods, C-cell tumors. The FDA labels for approved GLP-1 receptor agonists in this class carry boxed warnings and contraindications tied to personal or family history of MTC or MEN2; the rationale and rodent-human species-difference literature is summarized in Bjerre Knudsen et al., Endocrinology 2010 (NLM 20484460). A reader encountering MEN2 in the Open Assay corpus is typically encountering a citation to that preclinical-safety literature or to the MEN2 phenotype as a historical reference point for how C-cell biology is studied.

Open Assay's treatment

Open Assay cites MEN2 in the context of published preclinical and regulatory science for peptides in the incretin class; the category is bibliographic, not clinical. Listings point to specific published sources (review articles, FDA labels, primary preclinical studies) and do not extrapolate to any use of research materials.